Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Still testing your household for COVID-19 due to being immunocompromised or 65 or older? The ImmunoCARE Study might be right for you. The risks associated with COVID-19 infection are higher for immunocompromised individuals and people over 65 than the general public. Researchers want to determine if an at-home test that may detect COVID sooner can reduce COVID-19 severity when paired with telehealth and faster access to care. If you are interested in participating, fill out the form below.
FILL OUT THE FORM BELOW TO APPLY
Your name and information will not be shared to third parties without your authorization.
ABOUT THE IMMUNOCARE STUDY
WHO CAN ENROLL
Enrollment in the ImmunoCARE study is available to individuals who are moderately to severely immunocompromised. Participants must be able to provide documentation from a medical provider confirming their diagnosis.
Additional inclusion criteria includes:
• Living in the United States
• 18 years or older
• Vaccinated against COVID-19
• Participants will be asked to:
-Use a compatible smartphone, including camera and Bluetooth
-Show documentation of diagnosis/treatment either through connecting through an insurance portal or manually sharing documents
-Complete surveys
-Use Cue Health App and tests
-Use MyDataHelps by Web or App
FREQUENTLY ASKED QUESTIONS
ImmunoCARE is an innovative research project to study whether repeated at-home tests, on-demand telemedicine, and quick delivery of medication for those who test positive for COVID-19 can reduce COVID-19 severity in immunocompromised people.
Yes, all participants need to be at least 65 years of age OR have a medically confirmed condition or treatment that causes immune deficiency. If you fit into any of the following, you may qualify:
-Symptomatic HIV
-Graft versus host disease
-Immunoglobulin deficiency/Immunodeficiency
-Receiving immunosuppressive therapy
-Leukemia
-Lymphoma (Hodgkin or non-Hodgkin)
-Metastatic Cancer
-Multiple Myeloma
-Solid organ malignancy
-Transplant, hematopoietic stem cell
-Transplant, solid organ
-65 years or older
ImmunoCARE is a joint research project from Scripps Research – a renowned biomedical research organization — and Cue Health, a leading health care technology company that develops portable diagnostic tests for at-home use.
As with most research studies, there is an intervention group and a control group in this study. Only the intervention group will receive the Cue tests, telehealth care, and medication delivery. If you are in the control group, you will be asked to complete the study surveys and continue your COVID precautions as usual. Compensation is the same for both groups: Up to $100 in Amazon gift cards.
All study-related devices and medications are provided at no cost for those in the intervention group. Participants will never pay any costs to the study and are eligible to receive up to $100 in Amazon gift cards.
Cue at-home COVID tests are FDA approved compact and portable self-testing systems that can be used without a prescription. Test results take only 20 minutes and can detect small amounts of virus in people with or without symptoms.
Study participants that are assigned to the group that receives the Cue tests will receive the Cue testing device and 10 cartridges a month that may be used for the household or anyone who could expose you to COVID.
Yes. Your personal and health information will only be used for the purposes of the study and is never shared with unauthorized 3 rd parties.
Please note: 1nHealth may store your data in a confidential and secure database. That personal information will never be shared or sold with any other persons or organizations not associated with 1nHealth. 1nHealth may/will use personal information to contact you directly by phone and/or email for matters related to potential participation in clinical trials, studies, and projects for which the potential participant may qualify. See our Privacy Policy for more details.